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Background: The odontopathogenic virulence factor 
gingipain RgpB is produced as a zymogen to prevent 
intracellular activity prior to secretion. 
Results: The structure of the complex between the pro-
domain and the catalytic moiety of RgpB has been 
determined. 
Conclusion: RgpB is kept latent by a novel molecular 
mechanism. 
Significance: The structural details should enable to design 
small-molecule inhibitors to inhibit RgpB in a non-covalent 
manner. 
SUMMARY 
Zymogenicity is a regulatory mechanism which 
prevents inadequate catalytic activity in the wrong 
context. It plays a central role in maintaining microbial 
virulence factors in an inactive form inside the pathogen 
until secretion. Among these virulence factors is the 
cysteine peptidase gingipain B (RgpB), which is the 
major virulence factor secreted by the 
periodontopathogen Porphyromonas gingivalis that 
attacks host vasculature and defense proteins. The 
structure of the complex between soluble mature RgpB, 
consisting of a catalytic domain and an 
immunoglobulin-superfamily domain, and its 205-
residue N-terminal pro-domain, the largest structurally 
characterized to date for a cysteine peptidase, reveals a 
novel fold for the pro-domain that is distantly related to 
sugar-binding lectins. It attaches laterally to the 
catalytic domain through a large concave surface. The 
main determinant for latency is a surface “inhibitory 
loop”, which approaches the active-site cleft of the 
enzyme on its non-primed side in a substrate-like 
manner. It inserts an arginine (R126) into the S1 pocket, 
thus matching the substrate specificity of the enzyme. 
Downstream of R126, the polypeptide leaves the cleft, 
thereby preventing cleavage. Moreover, the carbonyl 
group of R126 establishes a very strong hydrogen bond 
with the co-catalytic histidine, H440, pulling it away from 
the catalytic cysteine, C473, and towards E381, which 
probably plays a role orienting the side chain of H440 
during catalysis. The present results provide the 
structural determinants of zymogenic inhibition of 
RgpB by way of a novel inhibitory mechanism for 
peptidases in general and open the field for the design of 
novel inhibitory strategies in the treatment of human 
periodontal disease. 
Periodontitis is a biofilm-associated chronic 
inflammatory disease of the gums caused by bacterial 
infection, which affects 10-15% of adults worldwide and 
may result in tooth loss (1,2). Of the several hundreds of 
bacterial species that colonize the oral cavity, the key 
disease pathogens are Aggregatibacter (Actinobacillus) 
actinomycetemcomitans, Tannerella forsythia, Treponema 
denticola, and Porphyromonas gingivalis, the latter three 
forming the red complex, which is implicated in severe 
forms of the disease (3-5). P. gingivalis is an opportunistic 
pathogen found in up to 85% of periodontitis cases and its 
presence at the infection site is indicative of disease 
progression (6,7). The pathogen requires nutrients, such as 
heme or vitamin K, and anaerobic conditions for growth 
(2). As part of the process of infection, P. gingivalis 
invades host epithelial cells and macrophages, where it 
affects cell-cycle pathways and suppresses apoptosis, 
thereby circumventing the host immune response and 
prolonging its survival (2,8). The pathogen possesses 
several factors which participate in infection, such as the 
lipopolysaccharide, the capsular polysaccharide, the 
fimbriae, and, most importantly, cysteine proteinases, viz. 
gingipains K (Kgp) and R (RgpA and RgpB) (2,9,10). 
While the former factors are intrinsic components of the 
outer membrane of the pathogen, gingipains are true cell-
surface-anchored or soluble virulence factors that, when 
secreted, account for up to 85% of the total extracellular 
proteolytic activity of P. gingivalis (10,11). This activity is 
aimed at obtaining nutrients, cleavage of host-cell surface 
receptors, stimulation of protease-activated receptor 
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expression, and inactivation of cytokines and components 
of the complement system. These functions contribute to 
resistance of the pathogen to host bactericidal activity and 
maintenance of the chronic inflammatory condition at the 
site of infection (2). In addition, gingipains contribute to 
bleeding and vascular permeability by activating plasma 
kallikrein, degrading fibrinogen, and increasing the levels 
of thrombin and prothrombin, thus increasing the 
availability of heme needed for bacterial growth (12). 
These functions explain why gingipains are essential for 
bacterial survival and the pathological outcome of 
periodontitis (3,10,13). 
As occurs with most proteolytic enzymes, the 
activity of gingipains must be regulated to prevent 
undesired intracellular proteolysis yet yield full activity 
once secreted (14). In general, such activity control occurs 
at the transcriptional level, through compartmentalization 
or allostery, or through inhibition by specific protein 
inhibitors. Another regulatory mechanism is zymogenic 
latency (15), which is observed for gingipains, and is 
carried out mostly by N-terminal pro-peptides or pro-
domains (PDs). These usually prevent substrates from 
binding to the active-site cleft of the cognate catalytic 
domain (CD) and are mostly removed by limited 
proteolysis during maturation (15-17). Such PDs often fold 
independently and guide on their part the folding process of 
the CD (18); they may also act as intra-molecular 
chaperones or inhibitors of the mature enzymes in trans—
as described for RgpB (19)—and in the intracellular sorting 
of the zymogen (15). Therefore, the study of the molecular 
mechanisms by which peptidases maintain latency is 
indispensable to the understanding of their basic mode of 
action. It also paves the way for the design of inhibitors 
that mimic the latent state so as to modulate proteolytic 
activity as part of a therapeutic approach. Detailed 3D 
structural information can contribute much to this 
understanding (20). 
Among gingipains, Kgp is specific for peptide 
bonds after lysines, while RgpA and RgpB are arginine-
specific (3,21). These enzymes are multi-domain proteins 
comprising at least a signal peptide, a PD, a CD, an 
immunoglobulin-superfamily domain (IgSF), and a C-
terminal domain, as found in the 736-residue RgpB 
spanning, respectively, 24, 205, 351, 87, and 69 residues  
(3). RgpA has four additional hemagglutinin/adhesion 
domains (termed RgpAA1-RgpAA4) inserted between the 
IgSF and the C-terminal domain, thus totaling 1,706 
residues. Kgp may have between three and five such 
domains (termed KgpAA1-KgpAA5) depending on the 
bacterial strain, thus totaling 1,723-1,732 residues (3). The 
CDs of gingipains distantly resemble caspase cysteine 
proteinases as revealed by the crystal structure of mature 
RgpB of P. gingivalis strain HG66 (22), and are grouped 
into MEROPS database family C25 
(http://merops.sanger.ac.uk; (23)).  
In order to understand the biochemical 
determinants of zymogenicity in gingipains, we analyzed 
the structure of the complex between the mature enzyme 
moiety (CD+IgSF domains) and the PD of RgpB from P. 
gingivalis strain W83. The results revealed a novel 
molecular mechanism of inhibition of peptidases and could 
thus pave the way for the design of novel inhibitory 
strategies that may help in palliating the effects of 
periodontal disease. 
 
EXPERIMENTAL PROCEDURES 
 
Protein production and complex formation — The 
wild-type PD of Porphyromonas gingivalis strain W83 
gingipain R2 alias RgpB proteinase (see UniProt database 
access code P95493) was obtained as reported elsewhere. 
Briefly, the coding sequence (Q25-R229) was cloned into 
the pGEX-6P-1 expression vector using BamHI/XhoI 
restriction sites, which attached an N-terminal 
glutathione-S-transferase-tag and a PreScission protease 
cleavage site. The vector was transformed into 
Escherichia coli BL21 (DE3) cells, and overexpression 
was induced with isopropyl-1-thio-β-D-
galactopyranoside. The protein was purified in a 
glutathione-Sepharose High Performance column, cleaved 
with PreScission protease, and passed again through 
glutathione-Sepharose. The flow-through was 
concentrated by ultrafiltration. The final purified protein 
contained an N-terminal extension of GPLGS as the result 
of the cloning strategy. The CD plus the IgSF (residues 
Y230-G662), fused to a C-terminal hexahistidine tag for 
purification, was purified from culture medium of the P. 
gingivalis strain W83 bearing a modified rgpB gene, in 
which a sequence encoding six histidine residues had 
been inserted in frame at the junction between the IgSF 
and the C-terminal domain. This construct results in the 
secretion of soluble RgpB with a C-terminal His-tag as 
described (24). For complex formation, RgpB (15mg) was 
pre-activated in gel filtration buffer (50mM sodium 
phosphate, 0.15M sodium chloride, pH 7.2) freshly 
supplemented with 10mM L-cysteine for 10min.  The 
activated RgpB-6xHis was then treated with 1mM N-[5-
amino-L-1-(2-chloroacetyl)pentyl]-4-methyl-
benzenesulfonamide (TLCK).  After 10-15min 
preincubation, the PD was added in 1.5-molar excess with 
respect to RgpB and the reaction mixture was incubated 
for another 15min. All incubations were performed at 
room temperature.  The complex was then separated from 
excess PD and TLCK by gel filtration on a Superdex 75 
10/60 column (GE Health).  The purity of the complex 
was evaluated by native PAGE and the protein 
concentration was determined by BCA assay (Sigma). 
The stability of the complex was assessed by following 
activity over time after incubation at 37ºC. No catalytic 
activity was observed after one week. This finding 
correlated well with purified full-length intact pro-RgpB 
undergoing auto-cleavage at the maturation site (R229-
Y230) but showing no significant catalytic activity even 
after two weeks of incubation. 
Crystallization and structure determination — 
Crystallization assays were performed by the sitting-drop 
vapor diffusion method. Reservoir solutions were prepared 
by a Tecan robot and 100-nL crystallization drops were 
dispensed on 96x2-well MRC plates (Innovadyne) by a 
Phoenix nanodrop robot (Art Robbins) at the High-
Throughput Crystallography Platform (PAC) at Barcelona 
Science Park. Plates were stored in Bruker steady-
temperature crystal farms at 4°C and 20ºC. Successful 
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conditions were scaled up to the microliter range with 24-
well Cryschem crystallization dishes (Hampton Research). 
Best crystals were obtained at 20ºC with protein complex 
solution (9.1mg/mL in 5mM Tris·HCl pH 7.4; 1mM 1,4-
dithio-DL-threitol [DTT]; 1mM TLCK) and 14% 
polyethylene glycol 6000; 0.1M sodium acetate pH5.0; 
0.2M calcium chloride as reservoir solution (with barium 
chloride as an additive) from 1:1µL or 2:1µL drops. 
Crystals were cryo-protected by immersion in harvesting 
solution (21% polyethylene glycol 6000; 0.1M sodium 
acetate pH5.0; 0.2M calcium chloride; 20%[v/v] glycerol). 
A complete diffraction dataset was collected from a liquid-
N2 flash-cryo-cooled crystal at 100K (provided by an 
Oxford Cryosystems 700 series cryostream) on an ADSC 
Q315R CCD detector at beam line ID14-4 of the European 
Synchrotron Radiation Facility (ESRF, Grenoble, France) 
within the Block Allocation Group "BAG Barcelona.” This 
crystal was monoclinic and contained four PD/CD+IgSF 
complexes per asymmetric unit. Diffraction data were 
integrated, scaled, merged, and reduced with programs 
XDS and XSCALE (25) (see Table 1).  
The structure of the PD/CD+IgSF RgpB complex 
was solved by likelihood-scoring molecular replacement 
with program PHASER (26) using the coordinates of the 
protein part only of mature RgpB of P. gingivalis strain 
HG66 (GenBank AAB41892; 97% sequence identity; 
Protein Data Bank [PDB] access code 1CVR; (22)). These 
calculations rendered four unambiguous solutions with 
values for the rotation/translation function Z-scores of 
18.6/18.7, 18.5/40.0, 22.6/62.3, and 19.6/73.1, respectively, 
and confirmed space group P21 as the correct one. 
Subsequent density modification with program DM (27) 
under fourfold averaging rendered an electron-density map 
which enabled construction of most of the 205-residue PD 
for one of the four complexes on a Silicon Graphics 
Octane2 Workstation using program TURBO-FRODO 
(28). The position and orientation of the other three copies 
within the asymmetric unit were determined with PHASER. 
Subsequent model building alternated with crystallographic 
refinement with program BUSTER/TNT (29), which 
included TLS refinement and NCS restraints, until 
completion of the model. The final model contained four 
PDs (chains A [R31-S204+T210-A227], C [G30-L205+F211-R229], 
E [G30-L205+F211-T228], and G [R31-S204+F211-E226]) and four 
cognate CD+IgSF moieties (chains B [G239-E661], D, F, and 
H [all N238-E661]). Within each catalytic moiety, the CDs 
were much more rigid and better defined by proper electron 
density than the cognate IgSFs; within each CD, loop 
Lα7η3 (~530s) was flexible and traced based on weak 
electron density to preserve chain continuity. In addition to 
the protein chains, one Ba2+ (tentatively assigned based on 
the electron density map and presence in the crystallization 
conditions) and three Ca2+ cations were identified for each 
CD+IgSF moiety. Furthermore, in addition to a single 
magnesium and tris cation, two further tentatively-assigned 
calcium and three sodium cations, as well as one chloride 
anion, one glycerol molecule, and 858 solvent molecules 
completed the model. Each of the four catalytic cysteine 
residues (C473) evinced extra electron density for its side 
chain, which we attribute to the purification strategy (see 
above) and conservatively interpreted as a methylsulfino 
group (residue type CSD). P532 of chain H and two residues 
of each CD (S449 and V474) were the only Ramachandran 
outliers of the entire structure (see Table 1). The latter two 
were also outliers in the mature chloromethylketone-
complex structure (22) and are unambiguously defined by 
proper electron density. Superposition of the three 
complexes CD, EF, and GH onto AB, respectively, 
revealed 612 common Cα atoms deviating less than 3Å, 
which gave rise to rmsd values of 0.75Å, 0.55Å, and 0.48Å, 
respectively, and indicated close similarity of the structures. 
This was confirmed by an independent superposition of the 
four CDs, which revealed very similar orientations and 
positions for the cognate PDs, with just marginal 
displacements on the proteinase distal surface (max. 3.8Å at 
E197). Accordingly, the four complexes were considered 
equivalent and the results and discussion hereafter refer to 
complex AB, which had slightly lower overall thermal 
displacement parameters (A/B: 41.5Å2/35.1Å2, C/D: 
46.2Å2/38.1Å2, E/F: 47.5Å2/37.8Å2, and G/H: 
48.4Å2/36.7Å2), unless otherwise stated. Wherever 
distances, angles, etc. are mentioned, the range found in all 
four complexes is indicated. 
Miscellaneous — Figures were prepared with 
program CHIMERA (30). Interaction surfaces (taken as 
half of the surface area buried at a complex interface) were 
calculated with CNS (31). Structure similarities were 
investigated with DALI (32). Model validation was 
performed with MOLPROBITY (33) and the 
WHATCHECK routine of WHATIF (34). The final 
coordinates of the complex between P. gingivalis RgpB PD 
and the CD+IgSF moiety have been deposited with the 
PDB at www.pdb.org (access code 4IEF). 
 
RESULTS AND DISCUSSION 
 
An experimental model of pro-RgpB — All 
attempts to crystallize intact full-length pro-RgpB for 
structural studies failed. Accordingly, the PD (residues Q25-
R229) and the mature moiety (residues Y230-G662) of pro-
RgpB from P. gingivalis strain W83 were produced 
separately and mixed to yield the zymogenic complex (see 
Experimental procedures). Four such complexes were 
found in the asymmetric unit of the crystal structure, which 
was determined by likelihood-scoring molecular 
replacement and averaging techniques, and refined with 
diffraction data to 2.3Å resolution (see Table 1). 
Superposition of the respective mature moieties revealed 
very similar relative arrangements of the four PDs. In 
addition, the distances (20-26Å) between the last residues 
of the PD moieties defined in the electron density 
(E226/R229) and the first of the respective CDs (N238/G239), 
both on the surface, could easily be bridged by the missing 
8-11 residues running along the molecular surface. 
Accordingly, the present complex provides a bona fide 
model of the intact zymogen, which correlates well with the 
strong inhibitory capacity of the PD on CD+IgSF in trans. 
The biochemical and kinetic analysis of the interaction 
revealed a non-competitive mode of interaction leading to 
formation of the 1:1 stoichiometric complex, which was 
stable in native PAGE and size-exclusion chromatography. 
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The stability obeyed to an apparent inhibition constant in 
the low nanomolar range (Ki=6.2±1.0nM). The very tight 
inhibitory interaction between the PD and the mature 
enzyme suggests existence of a yet unknown mechanism 
facilitating dissociation of the complex and degradation of 
the PD in vivo. At present we can only speculate on the 
nature of this mechanism. It can be related to glycosylation 
of the gingipain during the secretion process. Alternatively, 
one of the components of the PorSS secretion system, 
which is engaged in secretion of virulence factors for 
periodontopathogenicity  (35), could displace the PD during 
pro-RgpB translocation across the outer membrane and 
unleash activity. 
A pro-domain with a novel fold — The PD is 
defined by the electron density for residues G30/R31-
E226/R229 and has the overall shape of a croissant with 
maximal dimensions ~60x35x20Å (Fig. 1A,B). It consists 
of a central eleven-stranded β-core (strands βI-βXI) divided 
in two antiparallel β-sandwiches, 1 and 2, and decorated on 
the surface with an α-helix (αI) and two 310-helices (ηI and 
ηII; see Fig. 1C,D). The two sandwiches are held together 
by a continuous hydrophobic core that reaches from L37, 
L92, and M223 on the right side of sandwich 1 to Y175, P177, 
and K180 on the left of sandwich 2 (view as in Fig. 1C). 
Sandwich 1 consists of a three-stranded back sheet (strands 
βV, βIX, and βVII+βVIII) and a four-stranded front sheet 
(strands βI, βII, βXI, and βVI; see Fig. 1C,D). Strands βXI 
and βVI are N- and C-terminally extended beyond the 
limits of the sandwich, respectively, and bent by ~50-60º. 
In this manner, they also contribute to the three-stranded 
front sheet of sandwich 2 (strands βVI, βIX, and βX), 
which is packed against a two-stranded back sheet (strands 
βIII and βIV). The two sandwiches are roughly 
perpendicular to each other, both for the direction of the 
contributing strands and the planes of the sheets (Fig. 
1C,D). The strand connectivity of the two sandwiches is 
such that a first β-ribbon at the top of the front sheet of 
sandwich 1 (ribbon βIβII) is linked to the β-ribbon that 
creates the back sheet of sandwich 2 (βIIIβIV). This, in 
turn, ends in a loop connecting strands βIV and βV 
(LβIVβV), which is the top strand of the back sheet of 
sandwich 1. After βV, the chain enters the bottom strand of 
the front sheet of sandwich 1, βVI (Fig. 1C,D), the second 
half of which is the top strand of the front sheet of 
sandwich 2. After βVI, a 39-residue loop segment runs 
across the bottom surface of PD. This loop includes 310-
helices ηI and ηII and encompasses a so-called “inhibitory 
loop” (see below; Fig. 1C). This long loop leads to the 
bottom strand of the back sheet of sandwich 1, which is 
split in two, βVII and βVIII. The latter contributes to a β-
ribbon together with the central back-sheet strand of 
sandwich 1, βIX. Thereafter, the polypeptide enters a β-
ribbon (βXβXI), which creates the bottom of the front sheet 
of sandwich 2. As described for βVI, βXI is also extended 
and gives rise to the third strand (top to bottom) of the front 
sheet of sandwich 1 before leaving the β-core of the PD 
(Fig. 1C,D). Thereafter, the chain passes through a flexible 
segment on the right surface, which is disordered at 
L205/V206-S209/T210 and ends at the surface-located C-
terminal helix αI on the back of sandwich 1, and finishes at 
E226/R229.  
Structural similarity searches identified agglutinin 
from the roman snail, Helix pomatia, as the closest structural 
relative of the PD (PDB 2CE6; (36); Z-score=6.3; 
rmsd=2.7Å for 89 common residues according to program 
DALI (37)). This is a hexameric sugar-binding lectin from 
the albumen gland of the gastropod and part of its innate 
immune system. It belongs to a family of sugar-binding 
proteins mostly from invertebrates, which also includes 
discoidin C-terminal domain (PDB 2W94), and is a 3+3 
pure β-sandwich. Upon superposition of the PD and 
agglutinin, it becomes evident that the latter resembles PD 
sandwich 1, both in connectivity and topology (Fig. 1E). 
However, the PD shows an additional β-strand, the N-
terminal βI, and, most importantly, the second sandwich and 
the unique loop structures including the two 310-helices and 
the C-terminal α-helix. All-β domains similar to agglutinin 
are also present in glycolytic enzymes, i.e. sugar-binding 
proteins, such as endocellulase 9G (PDB 1G87), β-
xylosidase (PDB 1W91), and endogluceramidase II (PDB 
2OSX), as well as in the sugar-binding cellulosomal 
scaffolding protein A (PDB 4B9F), all of which were also 
identified as structurally related to the PD but match PD 
sandwich 1 only. We conclude that the PD of RgpB has a 
novel fold, hitherto unseen in peptidase zymogens and 
distantly related to functionally-unrelated sugar-binding 
proteins. 
The mature enzyme moiety — The structure of the 
mature enzyme moiety within the zymogenic complex 
resembles a molar, with its crown, tooth body, and root. Its 
superposition onto the structure of a covalent complex of a 
closely-related mature enzyme moiety from a distinct 
bacterial strain with D-Phe-Phe-Arg-chloromethylketone 
(PDB 1CVR; (3,22)) reveals that, with the exception of 
some minor changes in side-chain conformations (see next 
section), the entire structure, including the active-site cleft 
and the surrounding moiety, is conserved, i.e. the zymogenic 
conformation of CD+IgSF induced by the PD reveals that 
the enzyme is probably in a competent conformation in the 
zymogen, as is often observed in peptidases, thus suggesting 
inhibition is mediated by competition with the substrate 
(38). Briefly, the CD (N238/G239-P580) is subdivided into an 
N-terminal (or A-) sub-domain (NSD; N238/G239-E345) and a 
C-terminal (or B-) sub-domain (CSD; S346-P580). Both sub-
domains are α/β-moieties consisting of a central β-sheet, a 
four-stranded parallel one in the NSD and a six-stranded one 
parallel for all its strands except the outermost top one in the 
CSD (see Fig. 2B; NSD on top, CSD at bottom). This strand 
contacts the NSD β-sheet in an approximately perpendicular 
manner (see also Fig. 2 in (22)). NSD is decorated with one 
helix and two helices plus a short β-ribbon, respectively, on 
either side of the sheet. The CSD sheet has four helices and 
three helices plus a small three-stranded antiparallel β-sheet, 
respectively, on either side (Fig. 2B). One calcium ion is 
found in both the NSD and the CSD (the latter cation is 
most likely a barium in the present zymogenic structure due 
to the crystallization conditions; see Experimental 
procedures), and a further one is present at the sub-domain 
interface (Fig. 2B).  
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The active-site cleft is found at the “masticating 
surface” (22) of the molar crown and is formed by the CSD. 
As with enzymes with an α/β-hydrolase or PLEES fold 
(39,40), active-site residues are provided by loops and 
strands at the C-terminal edge of the central β-sheet, in this 
case that of the CSD: C473 is donated by the loop after the 
fourth strand (bottom to top in Fig. 2B), H440 by the first 
strand of the small three-stranded sheet inserted after the 
third strand, and E381 by a loop after the second strand. 
While cysteine-histidine dyads are common for cysteine 
proteinases, including MEROPS family C25 (41), the 
position and distance of E381 to H440 Nε2 in the mature 
enzyme (22) and in the present structure (Fig. 2B) suggests a 
role in protonation and, thus, side-chain orientation of the 
catalytic histidine during catalysis in RgpB, as described for 
an aspartate in the foot-and-mouth-disease-virus leader 
cysteine peptidase (42). In the present structure, the catalytic 
cysteine displayed extra density for its side chain beyond its 
Sγ atom possibly due to the purification procedure, which 
included reversible covalent-inhibition steps, and which we 
conservatively interpreted as a methylsulfino side chain (see 
Experimental procedures). On the opposite surface to the 
molar crown—where the active site is located—, the 
downstream IgSF (T581-E661) is inserted between the NSD 
and the CSD, thus mimicking the root of the molar. This 
domain is an antiparallel seven-stranded β-barrel or 3+4 β-
sandwich, which contains a fourth calcium-binding site on 
the surface (Fig. 2A). Its fold corresponds to that of classic 
immunoglobulin-like domains (43) as found in, e.g., α2-
macroglobulin (44). 
Interaction between the pro-domain and the 
catalytic domain — By contrast with other zymogens that 
are inhibited by large, structured, globular domains, e.g. 
those of the metallocarboxypeptidase class (38), the PD does 
not frontally cover and shield the CD active-site cleft but, 
rather, attaches laterally through its concave croissant 
surface to the enzyme moiety (Fig. 2A,B). The interaction of 
the PD with the CD (no interaction is observed between the 
PD and the IgSF) occludes a surface of ~1,650Å2 (~16% of 
the total PD surface), which is within the range generally 
described for protein-protein complexes (1,250-1,750Å2; 
(45)). It shows a surface complementarity (Sc=0.75) that is 
likewise within the range reported for protein oligomers and 
protein/protein inhibitor interfaces (0.70-0.76; (46)). The 
interaction results from 82 contacts (<4Å), among them 
three salt bridges (D216-K536, E73-K553, and R126-D392), one 
protein-metal interaction, 21 hydrogen bonds, and 
hydrophobic interactions between 11 PD and 13 CD 
residues. Participating segments of the CD are provided by 
the interface between the sub-domains and the active-site 
cleft: G239, G296-T300, N331-F338, E381-D392, T438-H440, V471-
C473, N510-R518, N533-K536, N545-F548, E552-D557. Further 
interactions include the calcium ion of the NSD. The PD 
contributes with segments V68-I77 and S89-S91 (from βIV, 
LβIVβV, and βV), S155-R161 and V167-N169 (from βVII, 
βVIII, LβVIIIβIX, and βIX), and N201-I203 and F211-V221 
(from LβXIαI and αI). In particular, I159 O of PD replaces a 
solvent molecule binding the calcium ion of the NSD in the 
mature inhibitor-complex structure (PDB 1CVR; (22)). This 
ion has an overall octahedral co-ordination sphere and is 
further bound by NSD atoms V329 O, D332 Oδ2, Y334 O, and, 
bidentately, E336 Oδ1 and Oδ2, as well as by a solvent 
molecule. 
Notwithstanding, the most relevant interaction of 
the pro-domain with the catalytic moiety is exerted by the 
inhibitory loop (K121-Y135), which is part of the segment 
flanked by strand βVI and the 310-helix ηII and is inserted 
like a stinger into the non-primed side of the active-site 
cleft, so that R126-A127 occupies the position of a potential 
scissile bond. The inhibitory loop has a compact structure, 
which is contributed to by a tight 1,4-turn of type I (S125-
E128), 310-helix ηI (N129-I133), and a small hydrophobic core 
created by P130, I133, I124, and K121, which interacts with W513 
of the CD (Fig. 2D). The lateral ζ-ammonium group of K121 
also contributes to the compact structure of the inhibitory 
loop through a double hydrogen bond with the main chain at 
P130 and I133 (Fig. 2D). Superposition of the present 
zymogenic complex and the reported chloromethylketone-
bound enzyme, which mimics a substrate-bound form, 
reveals that segment I124-R126 of the pro-domain binds to the 
active-site cleft in a substrate-like manner, i.e. in extended 
conformation and in the correct orientation. This binding 
places S125 in cleft sub-site S2, I124 in S3, and, most 
importantly, R126 in S1, thus matching the specificity of 
RgpB (see Fig. 2C,D). The S1 specificity pocket is lined by 
Q511, V471, M517, H395, T438, and, at the bottom, D392, which 
establishes a bidentate salt-bridge with R126. In addition, the 
side chain of W513 closes the S1 pocket like a lid. Moreover, 
R126 also interacts with the catalytic H440: the carbonyl 
oxygen of R126 establishes a very strong hydrogen bond with 
H440 Nδ1 (2.3-2.6Å apart), causing the imidazole side chain 
to be rotated slightly around its χ1-angle, away from the 
catalytic cysteine and towards E381 (Fig. 3). This rotation, in 
turn, gives rise to a second strong hydrogen bond between 
one of the E381 carboxylate oxygens and H440 Nε2 (2.6-
2.9Å). This interference with the catalytic residues most 
likely prevents cleavage of the PD at R126-A127. In addition, 
the polypeptide chain folds back after R126 towards bulk 
solvent, so that the active-site cleft is free on its primed side, 
and this also leads the catalytic C473 Sγ atom to be too far 
apart (3.7-3.8Å) from R126-A127.  
A novel mechanism of zymogenic inhibition — 
Latency maintenance in cysteine proteinases (17,47) has 
been structurally studied for MEROPS family C1 members 
such as Carica papaya plant papain (48) and caricain (49), 
and mammalian cathepsins B, K, L, S, and X (50-57). In 
these cases, the CD and the active-site cleft are, overall, in a 
preformed competent conformation in the zymogens and the 
~60-100-residue PDs, which contain a globular part laterally 
attached to the CD, possess a C-terminal segment that runs 
across the entire active-site cleft in the opposite orientation 
to that of a substrate, thus blocking access to the cleft and 
preventing autolysis. Zymogens of family C14, in turn, 
include the structurally-studied mammalian caspases 1 (58); 
3 (59); 7 (60,61), and 8 (62,63); and the insect Drosophila 
caspase-9 ortholog DRONC (64) and Spodoptera frugiperda 
caspase-1 ortholog ((65) and PDB 2NN3). Caspases are 
oligomeric functional enzymes and activation cleavage 
entails major rearrangement of the loops flanking the active-
site cleft from an incompetent to a competent conformation. 
There are no truly globular PDs but, rather, short N-terminal 
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and/or internal peptides that are cleaved off during 
maturation, thus giving rise to two chains in the competent 
enzymes (60,61,66). Zymogenic activation has been also 
studied for Staphylococcus aureus staphopain B (67), a 
member of family C47. Here, a large 183-residue globular 
PD based on a barrel-sandwich hybrid possesses a loop in 
the middle of the structure that binds, in the opposite 
orientation to that of substrates, to the cleft of an overall 
competent CD but only blocks the primed side of the cleft. 
Streptococcus pyogenes exotoxin B (alias SpeB or 
streptopain) (68) and Prevotella intermedia interpain A (69) 
belong to family C10, and here a backing–helix of a ~115-
residue α/β-sandwich PD is inserted laterally into the cleft in 
the zymogen but does not completely block substrate access. 
Activation entails major rearrangement of a zymogenic 
hairpin and a latency flap, which leads to a large 
displacement of the catalytic histidine (69).  
In stark contrast, the description of the zymogenic 
complex of RgpB reported here demonstrates that the PD, 
the largest structurally-characterized to date for a cysteine 
peptidase with 205 residues, interacts laterally through a 
large surface with the CD. The distance from the activation 
cleavage site, R229-Y230, on the top back surface of the 
complex in Fig. 2B, to the catalytic cysteine, on the front 
bottom in Fig. 2B, is >40Å, strongly suggesting that 
cleavage and, thus, removal of the PD and activation of the 
CD occurs in trans, as previously suggested for the cysteine 
peptidase interpain A (69). The PD intrudes into the active-
site cleft through a structurally-cohered inhibitory loop in 
the middle of the domain, thus blocking access to non-
primed side of the cleft only. This mechanism is unlike 
previously reported ones and is thus unique for cysteine 
peptidases and peptidases in general. It will pave the way to 
designing small-molecule inhibitors that mimic the 
structure of the inhibitory loop and that inhibit RgpB in a 
non-covalent manner, and may contribute to the 
development of novel drugs to combat periodontitis. 
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FIGURE LEGENDS 
 
Figure 1 – General architecture of the RgpB pro-domain. (A) Ribbon-type plot of RgpB PD showing the 
regular secondary-structure elements (α- and 310-helices in magenta and labeled αI and ηI-ηII, respectively; β-strand as 
blue arrows and labeled βI-βXI) and the approximate overall dimensions of the molecule. The inhibitory loop, which 
includes the S1-intruding residue, R126, is also labeled. Two small black arrows pinpoint the residues flanking the 
disordered segment preceding the C-terminal helix αI. (B) and (C) depict orthogonal views of (A). (D) Topology 
scheme of RgpB PD roughly in the same orientation as in (C). Each regular secondary-structure element is labeled and 
marked with its limiting residues. (E) Superposition in wall-eye stereo of RgpB PD (turquoise) and Helix pomatia 
agglutinin (magenta; PDB 2CE6; (36)). 
Figure 2 – The zymogenic complex. (A) Ribbon-type plot in wall-eye stereo of the complex between the RgpB 
PD (in blue/magenta) and the mature RgpB moiety in front view. The latter consists of domains CD (in yellow/orange) 
and IgSF (in green/brown). The three calcium and the barium ions are depicted as red and magenta spheres, 
respectively. The inhibitory loop and the respective N- and C-termini are labeled, in turquoise for PD and in brown for 
CD+IgSF. R126 from the PD inhibitory loop and the active-site residues of CD—C473, H440, and E381—are further shown 
as sticks for reference of the active site. (B) Orthogonal view of (A) showing the CD in standard orientation (22,70), i.e. 
with the view into the active-site cleft, which runs horizontally from left (non-primed side) to right (primed side). (C) 
Cartoon of the complex in the orientations of (A)(left) and (B)(right) showing the regions of the PD and CD engaged in 
binding in dark blue and orange, respectively. The rest of each molecule is shown in turquoise and yellow, respectively. 
(D) Close-up view in wall-eye stereo of the area around the inhibitory loop delimited by a black rectangle in (C). The 
CD moiety is shown as a tan ribbon and selected residues are labeled and shown for their side chains as sticks with tan 
carbons. The inhibitory loop (K121-Y135) is shown as a stick model with carbons in turquoise. Selected residues are also 
labeled. The Ba2+ ion of the CD is depicted as a magenta sphere. Note that the catalytic cysteine, C473, is oxidized to 3-
sulfino-L-alanine (residue name CSD). 
Figure 3 – The preformed catalytic moiety. Ribbon-plot in wall-eye stereo showing the superposition of the 
CD in the present zymogenic complex (yellow) and its mature inhibitor-bound form (purple; PDB 1CVR; (22)) in 
standard orientation. The two calcium ions (red spheres) and the barium ion (magenta sphere) found in the CD 
correspond to the zymogenic complex structure. Selected active-site residues are shown as sticks for each structure, as 
is the covalent inhibitor, atom-colored with green carbons. 
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Table 1. Crystallographic data. 
Space group / cell constants (a,b, and c, in Å; β in º)  P21 / 84.4, 133.1, 109.8, 90.5 
Wavelength (Å)  0.9393 
No. of measurements / unique reflections  395,643  /  106,820 
Resolution range (Å) (outermost shell)   47.3 – 2.30 (2.36 – 2.30) 
Completeness (%)   99.2 (91.2) 
Rmerge a  0.070 (0.436) 
Rr.i.m. (= Rmeas) a  0.082 (0.540) 
Average intensity over stand. dev. (<[<I> / σ(<I>)]>)  15.2 (2.6) 
B-Factor (Wilson) (Å2) / Average multiplicity  40.9  /  3.7 (2.8) 
Resolution range used for refinement (Å)  ∞ – 2.30 
No. of reflections in working set / in test set  101,461 (5,323) 
Crystallographic Rfactor (free Rfactor) b  0.189 (0.225) 
No. of protein atoms / solvent molecules / ligands /  19,119 / 858 / 1 (CH2OH)2CHOH / 
     ions 14 Ca2+, 4 Ba2+, 1 Mg2+, 3 Na+, 1 Cl-, 1 (OHCH2)3C(NH3+) 
Rmsd from target values  
      bond lengths (Å)  / bond  angles (°)  0.008  /  1.04 
Overall average B-factor (Å2)  39.7 
Main-chain conformational angle analysis 
c 
      Residues in favored regions / outliers / all residues  2,395 / 9 / 2,438 
Values in parentheses refer to the outermost resolution shell. 
a Rrmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl); Rr.i.m.= Σhkl(nhkl /[nhkl-1])1/2 Σi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl); Rp.i.m.= Σhkl(1/[nhkl-
1])1/2 Σi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the i-th intensity measurement and nhkl the redundancy of reflection hkl—
including symmetry-related reflections—and <I(hkl)> its average intensity. Rr.i.m. (alias Rmeas) and Rp.i.m. are improved multiplicity-
weighted indicators of the quality of the data, the redundancy-independent merging R factor and the precision-indicating merging R 
factor. The latter is computed after averaging over multiple measurements (for details, see (71,72)).  
b Crystallographic Rfactor = Σhkl ||Fobs| - k |Fcalc|| / Σhkl |Fobs|, where k is a scaling factor, and Fobs and Fcalc are the observed and calculated 
structure factor amplitudes, respectively. This factor is calculated for the working-set reflections; free Rfactor, same for a test-set of reflections 
(>500) not used during refinement. 
c According to MOLPROBITY (73). 
 



